Vaping and the Immune System: What We're Learning From Biomarker Studies

The immune system is one of the earliest and most sensitive indicators of the biological effects of inhaled exposures, and the emerging biomarker literature on vaping and immune function tells a nuanced story. Cigarette smoke is profoundly immunosuppressive and pro-inflammatory simultaneously—it impairs the lung's ability to clear pathogens while driving the chronic inflammation that underlies COPD, atherosclerosis, and cancer. When smokers switch to vaping, many of these immune abnormalities begin to reverse. But the reversal is incomplete, and some immune parameters remain altered in ways that researchers are still working to understand. The immune system is the canary in the coal mine for the long-term health effects of vaping—and the canary is singing a complex song.

The most consistent finding across biomarker studies is the reversal of smoking-induced inflammation when smokers switch to vaping. C-reactive protein (CRP), fibrinogen, white blood cell count—standard clinical markers of systemic inflammation that are elevated in smokers and predict cardiovascular disease risk—decline significantly within weeks to months of switching. A 2024 systematic review of 25 biomarker studies found that exclusive vapers had inflammatory marker profiles that were substantially closer to never-smokers than to current smokers, with most markers falling to within the normal reference range. The clinical significance is substantial: systemic inflammation is a primary driver of the cardiovascular disease that kills more smokers than lung cancer, and the rapid normalization of inflammatory markers after switching suggests that vaping may dramatically reduce cardiovascular risk relative to continued smoking. The immune system is telling us, in the language of biomarkers, that eliminating combustion eliminates a major driver of inflammation.

The respiratory immune response tells a more complex story. Smoking impairs mucociliary clearance (the mechanism by which the lungs expel pathogens and particles), damages the epithelial barrier, and dysregulates the alveolar macrophage function that's the lung's first line of defense against infection. Switching to vaping partially reverses these impairments: mucociliary function improves (producing the 'quitter's cough' as cilia regenerate), epithelial barrier integrity partially recovers, and macrophage function shifts toward a less inflammatory phenotype. But some immune alterations persist. Studies of nasal and bronchial epithelial cells from vapers show persistent changes in gene expression related to immune defense, and some markers of oxidative stress remain elevated compared to never-smokers. The respiratory immune system of a vaper is healthier than that of a smoker but not as healthy as that of a never-smoker—the harm reduction is substantial but incomplete.

The infection risk data provides real-world evidence that complements the biomarker findings. Smokers are at elevated risk for respiratory infections—influenza, bacterial pneumonia, tuberculosis—and the mechanisms (impaired mucociliary clearance, dysregulated macrophage function) are well-established. Whether vapers share this elevated risk is uncertain: the studies are small, the follow-up is short, and the confounding (vapers are often former smokers, and their infection risk may reflect past smoking rather than current vaping) is difficult to disentangle. The largest study to date, a 2023 analysis of electronic health records from over 100,000 patients, found that exclusive vapers had respiratory infection rates that were intermediate between smokers and never-smokers—higher than never-smokers but substantially lower than smokers. The finding is consistent with the biomarker evidence: vaping improves immune function relative to smoking but doesn't fully normalize it.

The cancer surveillance implications of the immune biomarker data are both reassuring and cautionary. The reassuring finding is that biomarkers of DNA damage and oxidative stress—8-oxo-dG, DNA strand breaks, micronucleus formation—are substantially lower in vapers than smokers and, in some studies, comparable to never-smokers. These are the biomarkers most directly relevant to the genotoxic mechanisms that drive smoking-related cancer, and their normalization after switching suggests that vaping's cancer risk is likely to be dramatically lower than smoking's. The cautionary finding is that some epigenetic changes associated with smoking—DNA methylation patterns that predict future cancer risk—may persist after switching, at least in the short term. The epigenome has a long memory, and the cancer risk from decades of smoking may not be fully reversible by switching to vaping. The immune system is telling us that switching reduces ongoing damage but doesn't erase historical damage. The implication is clear: the best time to switch is before the damage accumulates. The second best time is now.

The autoimmune disease dimension is emerging as an important area of research with implications for specific patient populations. Smoking is a major risk factor for rheumatoid arthritis, lupus, and other autoimmune conditions, and the mechanisms involve smoking-induced changes to immune tolerance and autoantibody production. Whether vaping shares this risk is unknown—the latency period for autoimmune disease is long, and the vaping-exposed population hasn't been followed long enough to detect an effect. But the mechanistic evidence is tentatively reassuring: the specific immune pathways that smoking dysregulates to promote autoimmunity (citrullination of proteins, formation of neutrophil extracellular traps) are driven by combustion products that vaping eliminates. If this mechanistic evidence translates into clinical outcomes, switching from smoking to vaping could substantially reduce autoimmune disease risk in genetically susceptible individuals. The research is in its early stages but has significant implications for smokers with autoimmune conditions who are considering switching.

The immune biomarker literature on vaping is not just an academic exercise in characterizing biological effects. It's directly relevant to the clinical counseling of smokers considering switching, the regulatory evaluation of vaping products, and the public communication about relative risks. The immune system is providing real-time feedback about the biological consequences of the transition from smoking to vaping—and the feedback is, on balance, strongly positive. The inflammation is receding. The respiratory defenses are recovering. The DNA damage is declining. The immune system is not fully restored to its never-smoker baseline, and it may never be. But the improvement is dramatic, measurable, and clinically meaningful. The canary is singing. The question is whether we're listening.